Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

April 12, 2023

Study Completion Date

July 13, 2023

Conditions
Pancreatic Cancer Stage IV
Interventions
DRUG

Gemcitabine

1000 mg/m2 IV on days 1, 8, and 15 Q4W

DRUG

Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]

480mg IV on Day 1 Q4W

DRUG

Cabiralizumab

4mg/kg IV on day 1 and 15 Q4W

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Lustgarten Foundation

OTHER

lead

Hitendra Patel

OTHER